Avitide Eyes 2019 Profitability with Series E Financing

06:06 EDT 21 Jun 2017 | Genetic Engineering News

Avitide, a manufacturer and supplier of molecule-specific biopharmaceutical affinity purification solutions, said today it has raised an undisclosed amount in Series E financing. Avitide said it will use the proceeds to fund ongoing operations, with the goal of becoming profitable by 2019. The company focuses on delivering high-yield, high-purity, molecule-specific affinity resins on demand in three months or less. Avitide’s proprietary affinity separation technology is designed to enable its partners to speed up their bioprocess development timelines, reduce their program risk, achieve predictable commercial scalability, and lower their cost of manufacturing for batch and continuous operations. According to its website, Avitide has 17 partnered programs. The company says its affinity-purification platform has been used successfully to purify biomolecules that include enzymes, antibody-based therapeutics, recombinant vaccines, and gene therapies. “The Avitide platform is positioned at the convergence of multiple biopharmaceutical manufacturing trends,” Kevin Isett, Avitide’s CEO ...

Original Article: Avitide Eyes 2019 Profitability with Series E Financing


More From BioPortfolio on "Avitide Eyes 2019 Profitability with Series E Financing"

Quick Search


Relevant Topic

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...